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Abstract
Objective—Estimate association between postpartum antiretroviral adherence and breastmilk 
HIV-1 transmission
Design—Prospective cohort study
Methods—Mother-infant pairs were randomized after delivery to immediately begin receiving 
28 weeks of either triple maternal antiretrovirals (zidovudine, lamivudine, and either nevirapine, 
nelfinavir, or lopinavir-ritonavir) or daily infant nevirapine as part of the Breastfeeding, 
Antiretrovirals, and Nutrition study. Associations between postpartum antiretroviral adherence and 
rate of breastmilk HIV-1 transmission were estimated using Cox models. We measured adherence 
over four postpartum time intervals using pill count, suspension bottle weight, and maternal self-
report. Adherence was categorized and lagged by one interval. Missing adherence measures were 
multiply imputed. Infant HIV-1 infection was determined by DNA PCR every 2-6 weeks. The 
primary endpoint was infant HIV-1 infection by 38 weeks of age among infants alive and 
uninfected at 5 weeks.
Results—Analyses included 1479 mother-infant pairs and 45 transmission events. Using pill 
count and bottle weight information, 22-40% of mother-infant pairs at any given interval were 
<90% adherent. Having ≥90% adherence was associated with a 52% (95% CI 3-76%) relative 
reduction in the rate of breastmilk HIV-1 transmission, compared with having <90% adherence 
when controlling for study arm, breastfeeding status, and maternal characteristics. Complete case 
analysis rendered similar results (n=501; relative reduction 59%, 95% CI 6-82%).
Conclusion—Non-adherence to extended postpartum ART regimens in ‘real world’ settings is 
likely to be higher than that seen in BAN. Identifying mothers with difficulty adhering to 
antiretrovirals, and developing effective adherence interventions, will help maximize benefits of 
ARV provision throughout breastfeeding.
Keywords
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INTRODUCTION
The World Health Organization (WHO) recommends that pregnant and breastfeeding 
women with HIV infection receive antiretroviral therapy (ART) either throughout 
breastfeeding or lifelong in an effort to achieve global goals of eliminating new infant HIV 
infections and keeping their mothers alive.[1] Effective implementation of this WHO 
guidance relies on adherence to prescribed antiretroviral (ARV) regimens.[2] Maintaining 
ARV adherence has been challenging for patients, and predicting who will be non-adherent 
and intervening in an effective way has been challenging for prevention of mother-to-child 
HIV transmission (PMTCT) programs.[3-8] Almost one half of postpartum patients included 
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in a recent meta-analysis did not maintain an adherence level thought to be needed for 
virologic suppression (>80%).[9]
Non-adherence to ART and PMTCT regimens may occur for several reasons, including: 
time and financial costs of accessing care, stigma, forgetfulness or changes in routine, and 
side effects of medications.[6, 10-15] Among non-pregnant or breastfeeding adults, >95% 
adherence is thought to be needed to maintain virologic suppression when unboosted 
protease inhibitors (PI) are included in the ART regimen.[16] Pharmacokinetic boosting of 
PIs with drugs such as ritonavir has been used to extend the plasma half-life of the active PI 
by inhibiting drug metabolism.[17, 18] With boosted PIs, 80% adherence may be sufficient 
for non-pregnant or breastfeeding adults to achieve virologic suppression.[19-21]
Despite the efficacy of ART in PMTCT, transmission does occur even in the context of 
closely monitored clinical trials for poorly understood reasons.[22-26] In this paper, we use 
data from a recent randomized PMTCT trial in Malawi to: 1) estimate adherence to 
postpartum maternal triple ARVs or daily infant NVP using pill counts, bottle weights, and 
maternal self-report; 2) compare characteristics of mother-infant pairs by adherence 
category; and 3) quantify the effect of adherence to both maternal triple ARVs and extended 
daily infant NVP on breastmilk HIV-1 transmission.
METHODS
The Breastfeeding, Antiretrovirals and Nutrition (BAN) trial was conducted in Malawi 
between 2004 and 2010 using a factorial design to assess the benefit and safety of 
antiretroviral medications given either to infants or mothers to prevent HIV transmission 
during breastfeeding.[22] Mothers were recruited at antenatal clinics in Lilongwe. Eligibility 
criteria for mother-infant pairs included the following: antibody-confirmed maternal HIV 
infection, maternal CD4 ≥250 cells/μL (≥200 cells/μL before July 24, 2006), no previous 
antiretroviral drug use (including single dose NVP), infant birth weight ≥2000 grams, no 
infant or maternal condition that would preclude the use of a study drug, and able to enroll 
within 36 hours of delivery.[22]
All mothers and infants enrolled in BAN received one dose of NVP at delivery or birth and 
seven days of zidovudine and lamivudine postpartum; no antepartum antiretrovirals were 
given.[22] Mother-infant pairs were randomized after delivery to immediately begin one of 
the following postpartum PMTCT prophylaxis regimens: 1) 28 weeks of maternal triple 
antiretrovirals (maternal ARV); 2) 28 weeks of infant NVP; or 3) no further drugs 
postpartum (enhanced control).[22] Mothers were also randomized to either receive or not 
receive a lipid-based nutrient supplement throughout breastfeeding.[22] All mothers were 
advised to breastfeed exclusively for the first 24 weeks postpartum with weaning between 
24 and 28 weeks.[22] Details of the drug regimens and nutrition supplement have been 
reported previously.[27-29]
Ethical approval was obtained from the Malawi National Health Science Research 
Committee and the institutional review boards at the University of North Carolina at Chapel 
Hill and the U.S. Centers for Disease Control and Prevention.
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Mother-infant pairs randomized to the two treatment arms of BAN, maternal ARV (n=849) 
and infant NVP (n=852) were included. We excluded mother-infant pairs that were 
randomized to the enhanced control arm (n=668), and infants who had one of the following 
outcomes between birth and four weeks of age: HIV infection (n=86), death (n=6), lost to 
follow-up (n=84), or unknown breastfeeding status (n=46). Information on first-born 
multiples was used when multiple births occurred (n=31). Our analysis thus included a total 
of 1479 mother-infant pairs at risk of breastmilk HIV transmission between 5 and 38 weeks 
of age. Weeks were chosen based on adherence measure availability and to allow for the 
delayed effect of non-adherence on transmission.
Data analyses
Breastmilk HIV-1 transmission was determined by Roche Amplicor 1.5 DNA PCR (Roche 
Molecular Systems, Pleasanton, CA, USA) at 2, 12, 28, and 48 weeks to indicate infant 
HIV-1 status. PCR-positive results were confirmed by testing an additional blood specimen, 
and the window of infection was narrowed with tests of infant dried blood-spot specimens 
taken at 4, 6, 8, 18, 24, 32, and 36 weeks. The primary outcome was breastmilk 
transmission, defined as first positive infant PCR test between 5 and 38 weeks of age. The 
secondary outcome was time until either first detection of infant HIV-1 infection or infant 
death by 38 weeks. Death ascertainment procedures have been described previously.[27]
The main exposure of interest was adherence to the prescribed postpartum ARV regimen. 
We measured adherence two ways: 1) maternal ARV pill counts or infant NVP suspension 
bottle weights, taken by trained pharmacy staff (hereafter referred to as “adherence”); and 2) 
maternal self-report, using a standardized questionnaire (used in sensitivity analyses, 
hereafter referred to as “self-reported adherence”). Only pill counts and bottle weights 
measured on contiguous visits were used. Adherence was then calculated for the following 
time intervals: 2-4, 8-12, 13-18, and 24-28 weeks of age. Pill counts and bottle weights were 
not collected during weeks 5-7, and 19-23. For analysis purposes, the unobserved adherence 
during weeks 5-7 and 19-23 were assumed to be equal to the observed adherence during 
weeks 8-12 and 24-28, respectively. Adherence was calculated using the difference in the 
number of pills or grams returned at the current visit and the number distributed at the 
previous visit, compared to the number of pills or grams expected to be consumed between 
visits if perfectly compliant under BAN dosing regimens. [27]
Because all three prescribed ARV drugs are necessary for full regimen activity, we made 
separate calculations for each drug and used the lowest percentage of the three to define a 
mother's ARV adherence at a given interval. A cutoff of 90% was then used to dichotomize 
adherence (<90% adherent=non-adherent, ≥90% adherent=adherent). The choice of 
adherence cutoff was based on previous studies and the expected adherence distribution.[30]
Self-reported adherence was measured at 4, 8, 21, and 28 weeks postpartum and based on 
the mother's answer to the following question: “During the past three days excluding today, 
have you/your baby missed any doses of (name of each individual antiretroviral 
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prescribed)?” Self-reported adherence was considered a time-varying dichotomous variable 
(≥1 reported missed dose of any drug; no reported missed doses of any drugs).
Potential confounding variables consisted of randomization assignment, baseline 
demographic characteristics and health status information (Table 1), and time-dependent 
breastfeeding status. All covariates were measured as part of the BAN trial. Frequencies, 
means, and medians were also calculated, as appropriate, to compare characteristics of 
mother-infant pairs by exposure (adherence) and outcome (HIV-1 status) category. Binomial 
regression models using generalized estimating equations (GEE) and an exchangeable 
correlation matrix were used to test whether or not adherence changed over time.
A time-to-event Cox model was used to assess the association between adherence and the 
rate of breastmilk HIV-1 transmission and breastmilk HIV-1 transmission or infant death by 
38 weeks of age, adjusting for potential prognostic factors. Hazard ratios represent the 
transmission rate for mother-infant pairs that were ≥90% adherent relative to the 
transmission rate of pairs <90% adherent; relative reduction is defined as one minus the 
hazard ratio. Adherence was included in the Cox model as a time-varying covariate, lagged 
by one interval to ensure the exposure occurred prior to the outcome. Therefore, adherence 
was associated with transmission in the subsequent time interval. Mother-infant pairs lost to 
follow-up were censored at the time of their last PCR negative HIV-1 test.
Effect measure modification was assessed by comparing unadjusted and adjusted hazard 
ratio estimates and 95% confidence intervals using an interaction term between adherence 
and the variable of interest. Covariates producing adjusted hazard ratio estimates different 
enough to be clinically or programmatically relevant were considered effect measure 
modifiers. A directed acyclic graph (DAG) was used to identify potential confounders and a 
minimally sufficient adjustment set.[22, 27, 31] Given the limited number of outcomes, 
more parsimonious models were generated by removal of potential confounders that had 
minimal effect on the hazard ratio estimate or precision.
Multiple imputation was used to account for missing adherence measures.[32]. Adherence 
was assumed to be missing at random. The probability of being adherent for each missing 
adherence measure was predicted from a fitted logistic regression model comprised of 
variables believed a priori to be predictive of adherence and for which there was minimal 
missing data. Covariates used to predict adherence included ARV study arm, maternal age 
(continuous), parity (0, ≥1), marital status, (married, not married), education status 
(≤primary, >primary), baseline maternal CD4+ category (200-350, 351-500, >500), baseline 
maternal hemoglobin (<11mg, ≥11mg), previous visit(s) adherence, time-dependent 
breastfeeding status, infant's outcome, and log survival time. Missing adherence measures 
were imputed based on the logistic regression predicted probabilities of being ≥90% 
adherent or <90% adherent. Five hundred complete data sets were imputed. Unadjusted and 
adjusted Cox models were then fit to obtain parameter and variance estimates for each of the 
500 datasets, and these estimates were combined to obtain a final mean hazard ratio estimate 
and 95% confidence interval.[33]
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Two main sensitivity analyses were conducted to address self-reported adherence and 
baseline maternal viral load. First, we compared self-reported adherence with pill count and 
bottle weight adherence, and compared the association between adherence and breastmilk 
HIV-1 transmission using each adherence measurement method. To do this, self-reported 
adherence was considered as the main exposure in sensitivity analyses, instead of pill count 
or bottle weight adherence. Second, we assessed the impact of adjustment for baseline 
maternal viral load, which was not included in the main regression analyses. Baseline 
maternal viral load information was not available for 3 mother-infant pairs, including one 
mother-infant pair who experienced a HIV-1 transmission event. Due to the known 
association between viral load and HIV transmission, we included log10-transformed 
baseline maternal viral load in both the imputation and analysis models as a sensitivity 
analysis.
All data analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North 
Carolina, USA).
RESULTS
A total of 1479 mother-infant pairs and 45 transmission events were included in analyses 
(Figure 1). The median maternal age was 26 years [interquartile range (IQR): 23 to 29]. 
Most mothers were married (93%) and reported at least one previous live birth (87%) (Table 
1). Among those randomized to maternal ARVs, most received a boosted protease inhibitor 
regimen of zidovudine, lamivudine, and lopinavir-ritonavir (79%) (Table 1). Mothers had a 
median baseline CD4+ count of 477 per uL (IQR: 330 to 582), a median baseline log10 viral 
load of 4.1 copies per milliliter of blood (IQR: 3.6 to 4.7), and a median hemoglobin of 10.8 
grams per dL (IQR: 10.0 to 11.7). The median infant birth weight was 3.0 kg (IQR: 2.7 to 
3.3).
The overall postnatal MTCT rate was 5.1 infections per 100 person-years (95% confidence 
interval (CI) 3.8-6.8); rates by maternal and infant NVP arm were 5.4 (95% CI 3.6-8.1) and 
4.9 (95% CI 3.2-7.4) infections per 100 person-years, respectively. Overall, mean pill count 
or bottle weight adherence was 87% [median 0.98; IQR: 0.82 to 1.00], and did not 
meaningfully differ by study arm (maternal arm 87%, infant arm 86%). Adherence changed 
over time in both the maternal and infant arm (p<0.001), but no consistent pattern was 
identified (Table 2).
Among all mother-infant pairs with at least one pill count or bottle weight adherence 
measure, 22-40% were <90% adherent at any given interval (maternal ARV arm 24-42%, 
infant NVP arm 17-51%) (Table 2). A larger proportion of mother-infant pairs with a HIV-1 
transmission event were <90% adherent (41%) during any given interval compared with 
mother-infant pairs whose infants remained HIV-uninfected (33%) (Table 2), but the 
difference was not statistically significant (p=0.1). The postnatal MTCT rate between 5-38 
weeks of infant age was 3.0 infections per 100 person-years (95% CI 1.7-5.4) for adherent 
intervals, and 7.4 infections per 100 person-years (95% CI 4.7-12.3) for non-adherent 
intervals.
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A total of 501 mother-infant pairs had complete pill count or bottle weight adherence 
information (complete cases). Of these, 146 (29%) were always ≥90% adherent and 35 (7%) 
were never ≥90% adherent (Table 3).
Among complete cases, 23 experienced a breastmilk HIV-1 transmission event by 38 weeks 
of age (maternal ARV arm: 18, infant NVP arm: 5), and 28 experienced the composite 
outcome of breastmilk HIV-1 transmission or infant death by 38 weeks (maternal ARV arm: 
21, infant NVP arm: 7). Having >90% adherence was associated with a 60% relative 
reduction in the rate of breastmilk HIV-1 transmission by 38 weeks of age among complete 
cases, compared with having <90% adherence (Hazard Ratio (HR) 0.40; 95% CI 0.17-0.91) 
(Table 4). Adjustment for maternal age, baseline maternal CD4+ count, baseline maternal 
hemoglobin level, time-dependent breastfeeding status, and study arm had little impact (HR 
0.41, 95% CI 0.18-0.94) (Table 4).
Multiple imputation
Adherence measured by pill count and bottle weight was imputed for 29% (431/1479) of 
mother-infant pairs at 4 weeks, 27% (387/1411) at 12 weeks, 29% (401/1375) at 18 weeks, 
and 43% (560/1310) at 28 weeks. No variables were significant predictors of adherence at 
all time points.
Having ≥90% pill count or bottle weight adherence was associated with a 50% relative 
reduction in the rate of breastmilk HIV-1 transmission by 38 weeks of age, compared with 
having <90% adherence [unadjusted HR 0.50, 95% CI 0.25-0.99] when using multiply 
imputed data (Table 4). The estimated hazard ratio was similar when unadjusted Cox models 
were fit separately for each study arm [maternal ARV HR 0.51, 95% CI 0.21-1.21; infant 
NVP HR 0.48, 95% CI 0.16-1.44) (Table 4). Adjustment for potential confounding did not 
meaningfully change the hazard ratio estimate (HR 0.48; 95% CI 0.24-0.97) (Table 4).
Composite outcome: breastmilk HIV-1 transmission or infant death
Associations between adherence and the composite outcome of breastmilk HIV-1 
transmission or death did not appreciably differ from those using only HIV-transmission as 
the outcome (unadjusted HR 0.58, 95% CI 0.32-1.04; adjusted HR 0.59, 95% CI 0.33-1.06).
Sensitivity analyses
A total of 541 mother-infant pairs had complete self-reported adherence information. Of 
these, 22 experienced a breastmilk HIV-1 transmission event (maternal ARV arm: 16, infant 
NVP arm: 6). Overall, 92% of mothers self-reported missing no pills in the last three days. 
Self-reported adherence was similar by study arm (infant NVP: 0.93, maternal ARV: 0.90). 
Among complete cases, reporting missing no pills in the prior 3 days (100% self-reported 
adherence) was associated with a 74% relative reduction in the rate of breastmilk HIV-1 
transmission, compared with those self-reporting <100% adherence during the last three 
days (HR 0.26, 95% CI 0.09-0.71) and after adjusting for study arm, time-dependent 
breastfeeding status, and baseline maternal age, CD4+ count, and hemoglobin. The 
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association remained similar when using multiply imputed self-reported adherence (n=1479, 
adjusted HR 0.33, 95% CI 0.14-0.78).
Including baseline maternal viral load in the imputation and analysis model resulted in a 
nearly identical association between pill count or bottle weight adherence and the rate of 
breastmilk HIV-1 transmission (complete case HR 0.40, 95% CI 0.18-0.92; imputed HR 
0.49, 95% CI 0.25-0.97), compared to models that did not adjust for baseline maternal viral 
load. Similarly, including the control arm in analyses and allowing for potential differential 
detection of HIV among the infant NVP arm resulted in similar findings (supplemental 
material).
DISCUSSION
We have shown that adherence to antiretroviral regimens needs to be maintained throughout 
the breastfeeding period to maximize efforts to prevent breastmilk HIV-1 transmission and 
improve infant HIV-free survival. The strong association found between very high (≥90%) 
adherence and transmission is striking, reinforcing the importance of maintaining mother-
infant pairs in HIV care and providing effective adherence counseling messages. To our 
knowledge, this study was the first in a resource-limited setting that assessed adherence over 
time to an extended postpartum prophylaxis regimen using pill count, bottle weight, and 
maternal self-report. The extent of missing adherence data in our study underscores the 
difficulty in consistently assessing adherence to postpartum antiretroviral medications, even 
in a well-monitored clinical trial with intensive follow-up.
Non-adherence to ART has been associated with higher HIV viral loads in pregnant women, 
and compliance to short-course maternal zidovudine has been associated with decreased 
HIV-1 vertical transmission.[12, 34, 35] Maternal ARV adherence rates had a negative but 
not statistically significant correlation with MTCT rates in a recent meta-analysis.[9] 
However, most studies in the meta-analysis used short-course ARV regimens and reported 
only antepartum adherence.[9] In contrast, we measured postpartum adherence over four 
time intervals, and allowed adherence to vary over time. In addition, we used methods that 
account for missing adherence measures, infants lost to follow-up, and infant death.
The number of transmission events was relatively small despite the large sample size, 
reducing the precision of our estimates and preventing comparisons by study arm. However, 
we observed a substantial effect of adherence on breastmilk HIV-1 transmission despite the 
small number of transmission events.
Adherence levels found in BAN are similar to reported adherence from other randomized 
controlled trials of either extended infant or maternal antiretroviral prophylaxis during 
breastfeeding, and to a pooled postpartum adherence estimate.[9, 23, 24, 26, 36] However, 
direct adherence comparisons are difficult due to differences in definition and measurement 
of adherence across trials. Adherence may be measured using a variety of approaches 
ranging in sophistication, but all are imperfect.[37] Self-reported adherence has the most 
potential for bias (usually in the form of overestimating adherence) due to recall and social 
desirability bias, but is the measurement tool most often used because it is easy and 
DAVIS et al. Page 8













inexpensive to administer.[37] Adherence measurements based on pill count and suspension 
bottle weight are subject to manipulation, but are thought to have greater validity and take 
into account adherence over the entire monitoring period, rather than just the three days 
prior to the self-report assessment visit.[38] A consensual adherence measurement method is 
needed to facilitate inter-study comparisons. In our study, self-reported adherence was 
higher than adherence measured by pill count and bottle weight, with poor agreement 
between the two measures (supplemental material). However, both adherence measures 
resulted in a consistent association with breastmilk HIV-1 transmission, increasing the 
confidence in our findings.
We were unable to determine an adherence threshold for transmission prevention despite 
assessing multiple adherence cutoffs (e.g.: 80% and 95%) and imputing adherence as a 
continuous measure. Our findings suggest that the association between adherence and 
transmission is a continuum, with higher adherence leading to higher protection against 
transmission (results not shown). In addition, while determinants of maternal versus infant 
adherence likely differ, we were unable to ascertain such differences in this study.
When adherence data are skewed, presenting only one measure of central tendency (e.g., 
mean or median) may fail to convey the characteristics of the adherence distribution, and be 
misleading. For example, median adherence in our study was 98%, suggesting that no 
further action is needed to maintain high levels of postpartum adherence. Mean adherence 
was 87%, suggesting that some work is needed to improve adherence, but adherence 
remained high. In contrast, 22-40% of mother-infant pairs in our study were <90% adherent 
during each interval, suggesting that increased focus is needed to improve postpartum 
adherence. Variation in measures exemplifies the skewed left adherence distribution and 
implies that some mother-infant pairs had very low adherence, and that some had 
intermittent non-adherence. Given that transmission is associated with non-adherence, there 
is a need to consistently emphasize adherence throughout the postpartum period.
BAN study nurses counseled mothers on adherence, referencing pill counts and bottle 
weights. The extent of adherence monitoring and counseling in BAN greatly exceeds that 
conducted in most non-clinical trial settings. In ‘real-world’ settings, retention in HIV care 
as measured by non-missed appointments is generally used as a crude proxy for adherence, 
with other direct adherence measures rarely conducted. However, a patient's care-seeking 
and drug-taking behaviors are not necessarily synonymous.
Non-adherence did not account for all transmission events. Transmission may have occurred 
despite perfect adherence due to imperfection in our adherence measure, delay between 
maternal initiation of antiretrovirals and virologic suppression, antiretroviral drug resistance, 
or other unidentified processes. The number of visits that could be used to assess adherence 
resulted in inconsistent and extended time intervals between adherence measures. Adherence 
was held constant during the interval, and lagged to ensure the exposure occurred before the 
outcome. Therefore, measured adherence may not be the true adherence in the period 
immediately before transmission.
DAVIS et al. Page 9













Our results reinforce the need to focus on maintaining adherence to meet PMTCT goals. 
Furthermore, the extent of non-adherence in this heavily monitored clinical trial setting has 
important implications for adherence counseling messages, local PMTCT program planning 
efforts, and global modeling exercises predicting MTCT elimination. We measured 
adherence through 28 weeks postpartum. The time lag between maternal antiretroviral 
initiation and virologic suppression may partly explain the strong association found between 
what is generally deemed as very high adherence and breastmilk transmission, as very high 
adherence may be more important for preventing transmission during the first months of 
ARV initiation. Assessment of adherence and adherence-related outcomes throughout one to 
two years of breastfeeding is urgently needed.
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Refer to Web version on PubMed Central for supplementary material.
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Table 1
Baseline characteristics of 1479 mother-infant pairs.
Total
*
 (N=1479) HIV-1infected infant
**
 (N=45) HIV-1 uninfected infant
†
 (N=1434)
N (%) N (%) N (%)
Antiretroviral randomization
    Maternal antiretroviral 725 (49) 23 (51) 702 (49)
    Infant nevirapine 754 (51) 22 (49) 732 (51)
Nutritional randomization
    No supplement 733 (50) 17 (38) 716 (50)
    Received supplement 746 (50) 28 (62) 718 (50)
Mothers:
Age (years)
    15-25 720 (49) 30 (67) 690 (48)
    26-35 680 (46) 14 (31) 666 (47)
    36-45 76 (5) 1 (2) 75 (5)
Education
    Primary school only 941 (64) 29 (64) 912 (64)
    More than primary school 536 (36) 16 (36) 520 (36)
Married
    No 110 (7) 5 (11) 105 (7)
    Yes 1369 (93) 40 (89) 1329 (93)
Parity
    0 193 (13) 8 (18) 185 (13)
    >1 1280 (87) 37 (82) 1243 (87)
CD4+ count per mm3
    200-350 450 (30) 20 (44) 430 (30)
    351-500 478 (32) 13 (29) 465 (32)
    >500 551 (37) 12 (27) 539 (38)
Plasma viral load copies/mL
    ≤1,000 147 (10) 1 (2) 146 (10)
    1,001-10,000 425 (29) 7 (16) 418 (29)
    >10,000 904 (61) 36 (82) 868 (61)
Hemoglobin (g/dl)
    <11 783 (53) 35 (78) 748 (52)
    ≥11 696 (47) 10 (22) 686 (48)
ARV Regimen
‡
    Nevirapine based 20 (3) 0 (0) 20 (3)
    Nelfinavir based 124 (18) 5 (22) 119 (18)
    Lopinavir/ritonavir based 556 (79) 18 (78) 538 (79)
Infants
Sex
    Female 752 (51) 23 (51) 729 (51)
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Total
*
 (N=1479) HIV-1infected infant
**
 (N=45) HIV-1 uninfected infant
†
 (N=1434)
N (%) N (%) N (%)
    Male 727 (49) 22 (49) 705 (49)
Birth weight (kg)
    <2.5 106 (7) 7 (16) 99 (7)
    ≥2.5 1370 (93) 38 (84) 1332 (93)
*
Maternal plasma viral load was not available for 3 mothers, ARV regimen information was not available for 25 mothers randomized to maternal 
ARV arm, and infant birth weight was not available for 3 infants
**
Infant tested PCR-positive for HIV-1 between 5 and 38 weeks of age
†
Includes 16 infants that tested PCR-positive for HIV-1 after 38 weeks of age
‡
Among those randomized to maternal ARV arm.
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Table 2
Pill count and bottle weight adherence for mother-infant pairs with ≥1 adherence measure.






Maternal + Infant regimen
    Overall 0.87 0.22 0.98 0.82-1.00 33
    Week 4 1048 0.86 0.23 0.98 0.82-1.00 34
    Week 12 1024 0.91 0.19 1.00 0.91-1.00 22
    Week 18 974 0.87 0.19 0.97 0.76-1.00 37
    Week 28 750 0.82 0.27 0.96 0.74-1.00 40
Maternal regimen
    Overall 0.87 0.21 0.97 0.85-1.00 32
    Week 4 571 0.86 0.22 0.96 0.82-1.00 37
    Week 12 552 0.89 0.19 0.98 0.89-1.00 26
    Week 18 522 0.91 0.17 0.99 0.90-1.00 24
    Week 28 401 0.81 0.27 0.94 0.73-1.00 42
Infant regimen
    Overall 0.86 0.23 1.00 0.78-1.00 34
    Week 4 477 0.86 0.24 1.00 0.81-1.00 31
    Week 12 472 0.92 0.19 1.00 0.95-1.00 17
    Week 18 452 0.82 0.20 0.87 0.67-1.00 51
    Week 28 349 0.82 0.27 0.98 0.74-1.00 39
HIV-infected infants
    Overall 0.84 0.26 0.96 0.83-1.00 41
    Week 4 30 0.85 0.22 0.93 0.84-1.00 47
    Week 12 24 0.89 0.22 0.99 0.89-1.00 29
    Week 18 18 0.82 0.30 0.98 0.75-1.00 39
    Week 28 11 0.71 0.35 0.83 0.45-1.00 55
HIV-uninfected infants
    Overall 0.87 0.22 0.98 0.82-1.00 33
    Week 4 1018 0.86 0.23 0.99 0.82-1.00 34
    Week 12 1000 0.91 0.19 1.00 0.91-1.00 22
    Week 18 956 0.87 0.19 0.97 0.76-1.00 37






Having less than 90% pill count or bottle weight adherence is considered non-adherent.
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Table 3
Characteristics of mother-infant pairs with complete adherence information (n=501)
Total
* Always ≥90% adherent 
(n=146)
<90% adherent for ≥1 interval 
(n=355)








    Maternal antiretroviral 328 99 (30) 229 (70) 23 (7)
    Infant nevirapine 173 47 (27) 126 (73) 12 (7)
Nutritional randomization
    No supplement 230 71 (31) 159 (69) 17 (7)
    Received supplement 271 75 (28) 196 (72) 18 (7)
Mothers:
Age (years)
    15-25 208 66 (32) 142 (68) 18 (9)
    26-35 265 78 (29) 187 (71) 17 (6)
    36-45 27 2 (7) 25 (93) 0 (0)
Education
    Primary school only 316 90 (28) 226 (72) 19 (6)
    More than primary school 184 55 (30) 129 (70) 16 (9)
Married
    No 35 10 (29) 25 (71) 1 (3)
    Yes 466 136 (29) 330 (71) 34 (7)
Parity
    0 55 22 (40) 33 (60) 5 (9)
    ≥1 445 124 (28) 321 (72) 30 (7)
CD4+ count per mm3
    200-350 162 46 (28) 116 (72) 11 (7)
    351-500 151 41 (27) 110 (73) 11 (7)
    >500 188 59 (31) 129 (69) 13 (7)
Plasma viral load copies/mL
    ≤1,000 52 20 (38) 32 (62) 1 (2)
    1,001-10,000 135 42 (31) 93 (69) 3 (2)
    >10,000 313 83 (27) 230 (73) 31 (19)
Hemoglobin (g/dl)
    <11 262 74 (28) 188 (72) 20 (8)
    ≥11 239 72 (30) 167 (70) 15 (6)
ARV Regimen
‡
    Nevirapine based 9 4 (44) 5 (56) 1 (11)
    Nelfinavir based 46 13 (28) 33 (72) 6 (13)
    Lopinavir/ritonavir based 273 82 (30) 191 (70) 16 (6)
Infants
Sex
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Total
* Always ≥90% adherent 
(n=146)
<90% adherent for ≥1 interval 
(n=355)







    Female 262 67 (26) 195 (74) 20 (8)
    Male 239 79 (33) 160 (67) 15 (6)
Birth weight (kg)
    <2.5 36 17 (47) 19 (53) 3 (8)
    ≥2.5 465 129 (28) 336 (72) 32 (7)
*
Maternal age, education, parity, and viral load are missing for 1 mother
**
Columns are not mutually exclusive. Those 'never ≥ 90% adherent' are also included in the '<90% adherent for ≥1 interval' column.
†
Row percentages are presented
‡
Among those randomized to maternal ARV arm
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